Perindopril: An updated review of its use in hypertension

Drugs

Volumn 61, Issue 6, 2001, Pages 867-896

  Hurst, M ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; KININ; PERINDOPRIL; PROSTAGLANDIN;

ARTICLE; BLOOD PRESSURE REGULATION; BRAIN ARTERY; CLINICAL TRIAL; CORONARY ARTERY; COUGHING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; FIBRINOLYSIS; GLUCOSE METABOLISM; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID METABOLISM; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PROTEIN SYNTHESIS; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

PASSION FRUIT WOODINESS VIRUS;

EID: 0034985925     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00020     Document Type: Article

References (126)

1. Management of the hypertensive patient with coronary artery disease
2. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
3. The sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
4. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders
5. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects
6. 2 in patients with essential hypertension
7. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: Perindopril versus isradipine
8. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation
9. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension
10. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril
11. Efficacy and acceptability of perindopril in essential hypertension
12. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases
13. Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension
14. Perindopril versus captopril: Efficacy and acceptability in an Italian multicenter trial
15. A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension
16. Double-blind comparison of perindopril and captopril in hypertension: Effects on left ventricular morphology and function
17. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
18. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria
19. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients
20. A double-blind assessment, perindopril vs verapamil, of the effects on office and 24 HR ambulatory blood pressure and on left ventricular morphology
21. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade
22. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension
23. Effects of antihypertensive treatment on heart structure in mild essential hypertension
24. Effect of losartan and perindopril on plasma PAI-1 and fibrinogen in hypertensive type 2 diabetic patients
25. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension
26. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study
27. Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer
28. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure
29. Pharmacokinetics (PK) and pharmacodynamics (PD) of perindopril (P) and its active metabolite, perindoprilat (PL) in healthy subjects
30. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril
31. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects
32. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man
33. Effect of perindopril (S-9490) on blood pressure and renin-angiotensin aldosterone system in hypertensive men
34. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril
35. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers
36. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure
37. Formulary management of ACE inhibitors
38. Acute and chronic effects of perindopril on tissue angiotensin converting enzyme activity
39. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease
40. Twenty-four hour action of ACE inhibitors
41. Effects of perindopril on left ventricular mass and on diastolic function in mild-to-moderate hypertension
42. Determinants of left ventricular function before and after regression of myocardial hypertrophy in hypertension
43. Perindopril and physiologic responses to exercise
44. Effect of perindopril on 24-hour blood pressure levels and hemodynamic responses to physical and mental stress in elderly hypertensive patients
45. Non-invasive evaluation of arterial abnormalities in hypertensive patients
46. Influence of the angiotensin II type I receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
47. Effect of perindopril and amiloride/hydrochlorothiazide on haemodynamics and vessel wall properties of large arteries
48. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients
49. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease
50. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients
51. Beneficial effect of acute ACE inhibition on vasomotion and myocardial perfusion in type II diabetics with left ventricular hypertrophy
52. Pefindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke
53. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease
54. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives
55. Course of the left ventricular mass in a population of 893 hypertensive patients: Effects of therapeutic intervention with perindopril
56. Regression of mediato-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensinconverting enzyme inhibitor-based regimen in hypertensive patients
57. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy
58. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies
59. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric noninsulin-dependent diabetes mellitus
60. Comparison of the effects of angiotensin II antagonists and ACE inhibitors on renal handling of uric acid in hypertensive patients
61. Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients: 1-Year randomised, double-blind, parallel study vs atenolol
62. A double-blind randomised comparison of perindopril and ketanserin in the treatment of hypertension in elderly diabetic patients
63. Effects of perindopril on carbohydrate and lipoprotein metabolism in essential hypertension
64. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: Results of a double-blind multicenter study versus atenolol
65. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients
66. Effects of angiotensinconverting enzyme inhibitors on glucose and lipid metabolism in essential hypertension
67. Effects of perindopril on glucose and lipid metabolism in patients with mild-tomoderate essential hypertension and glucose intolerance
68. Effect of perindopril and of nitrendipine on plasma fibrinogen in overweight hypertensive patients
69. Effects of perindopril on serum lipids in hypertensive patients with hypedipidemia
70. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture
71. 2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men
72. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum
73. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects
74. Pharmacokinetics of perindopril and its metabolites in healthy volunteers
75. Specific and high affinity binding of perindoprilat, but not of perindopril to blood ACE
76. Effects of food on the pharmacokinetics and ACE-inhibition of perindopril in healthy volunteers
77. The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril
78. The pharmacokinetics of perindopril in patients with liver cirrhosis
79. ACE inhihitors: Drug interactions of clinical significance
80. Perindopnl as monotherapy in hypertension: A multicenter comparison of two dosing regimens
81. A dose-response study of perindopril in hypertension: Effects on blood pressure 6 and 24 h after dosing
82. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 b therapeutic coverage and beyond in patients with mild to moderate hypertension
83. Efficacy and safety of a fixed low-dose perindopril/indapamide combination in essential hypertension. A randomised controlled study
84. Safety and efficacy of perindopril/indapamide fixed combination in mild-to-moderate hypertension
85. Captopril versus perindopril: A double blind study in essential hypertension
86. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril
87. The differences between ACE inhibitors trough to peak ratios at 24-hour ambulatory monitoring (cross-over study)
88. A double-blind comparison of perindopril and enalapril on 24-h control of blood pressure in hypertensive patients
89. Clinical evaluation of monotherapy with perindopril, an ACE inhibitor, in the treatment of essential hypertension: Double-blind parallel comparison with enalapril
90. Comparative efficacy of perindopril and enalapril once daily using 24-hour ambulatory blood pressure monitoring
91. Once daily perindopnl versus slow release diltiazem in the treatment of mild to moderate essential hypertension
92. A double blind comparison of perindopril and atenolol in essential hypertension
93. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
94. Efficacy and safety of perindopril and hydrochlorothiazide in stage I-III hypertension
95. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: A double-blind multicentre study
96. Low-dose diuretic and/or dietary sodium restriction when blood pressure is resistant to ACE inhibitor
97. Perindopril 2mg/indapamide 0.625mg: Fixed low-dose combination
98. Perindopril postmarketing surveillance: A 12 month study in 47 351 hypertensive patients
99. Treatment of essential hypertension in general practice: An open-label study of 47,351 French hypertensive patients treated for one year with perindopril
100. Antihypertensive activity and acceptability based on clinical and laboratory parameters of perindopril: Chief results in 23,460 mild to moderate hypertension patients treated for 6 months in general practice
101. How important is 24-hour control of blood pressure?
102. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night
103. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males
104. Choosing the right ACE inhibitor: A guide to selection
105. Persistence of anti-hypertensive effect after missed dose of perindopril
106. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients
107. Efficacy and tolerance of a angiotensin converting enzyme, perindopril, in 2256 hypertensive patients aged 80 years or over treated for one year
108. Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly
109. The effect of antihypertensive treatment with Perindopril and Lacidipine on the incidence of silent ischemia in patients with hypertension
110. Blood pressure, stroke and coronary heart disease: Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
111. British Hypertension Society guidelines for hypertension management 1999: Summary
112. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients
113. Impact of aortic stiffness on survival in end-stage renal disease
114. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
115. Arterial stiffness and the development of hypertension: The ARIC study
116. Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension
117. Vascular remodeling and endothelial function in hypertensive patients: Effects of antihypertensive therapy
118. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy
119. Reversal of left ventricular hypertrophy in hypertensive patients; A meta-analysis of 109 treatment studies
120. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
121. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
122. European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease
123. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): Baseline demography of randomised subjects and BP changes after 18 months followup